EGFR and non-small cell lung carcinoma: Among treatment-naïve NSCLC patients with EGFR ex20ins, the progression-free survival (PFS) in the amivantamab plus chemotherapy group was significantly longer than that of the chemotherapy group (median, 11.4 months and 6.7 months, respectively) (42).